Denmark-based medical foundation Novo has used its quasi-corporate venturing unit to co-lead the £4m ($6.5m) series B round for Vantia Therapeutics, a UK-based drugs company.
Venture capital (VC) firm SV Life Sciences also co-led the B round, which included VC peer MVM Life Science Partners and all existing investors in Vantia.
MVM, SV and Novo had spun Vantia out from Ferring Pharmaceuticals with up to £19m in March 2008.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
